The FDA approved Eli Lilly’s once-daily weight-loss pill, Foundayo (orforglipron), on April 1, 2026. This drug is the first oral GLP-1 for weight management that patients can take at any time without food or water restrictions. This flexibility provides a significant convenience advantage over existing treatments.
The approval allows Lilly to compete directly against Novo Nordisk’s oral Wegovy. Analysts forecast multi-billion dollar sales potential as the drug captures a substantial share of the obesity market.
Lilly’s stock (LLY) rose nearly 4% on the day of the announcement. This performance significantly outpaced the broader market. The commercial launch for Foundayo begins on April 6, 2026.